Saturday 17 October 2026 Export PHIO’s income statement to Excel — free account

Phio Pharmaceuticals Corp.

In the quarter to June 2026, EPS grew 20.0% and free cash flow fell 58.7%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

0.87 0.06 −6.45%

Follow PHIO

Alert me

Market cap: $10.8M
P/E: 0.0×
Fwd P/E: −1.4×
Dividend yield: —
F-score: 1/9
Altman Z: −18.25
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.09

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	2	2	—	—	—	—	—	1	—	2	4	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 15.04%

Capital & Financial Ratios $m

Market Cap 10.75

Revenue 0.14

Net Income (12.90)

Free Cash Flow (12.21)

Net Debt (13.00)

Current Ratio 8.39

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (1.40)

P/S ratio 74.31

P/B ratio 0.80

Past 5Y EPS Growth —

This Y EPS Growth 0.34%

Next Y EPS Growth 57.79%

Next Y revenue growth (100.00%)

Next 5Y EPS Growth 59.13%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 51.57%

10-year low 10-year high

P/B against its own 10 years 52.12%

10-year low 10-year high

EV/FCF against its own 10 years 15.96%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	8	5	21	13
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	9	6	21	14

	2023	2024	2025	Q'26
Payables	1	0	0	1
ST’ Debt	—	—	—	—
Other	—	—	—	—
	2	1	1	2

Compound Annual Growth %

	10y	5y	3y
Sales	—	(21.62%)	3.39%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	8.53%	9.13%	22.96%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’19	0	—	—	—	0
’18	0	0	0	0	0
’17	—	—	—	—	0

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(4)	(4)	—	—	—
’25	(1)	(3)	(2)	(2)	(8)
’24	(2)	(2)	(2)	(1)	(7)
’23	(3)	(3)	(3)	(2)	(11)
’22	(3)	(2)	(4)	(3)	(12)
’21	(3)	(3)	(3)	(2)	(12)
’20	(2)	(2)	(2)	(3)	(9)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(4)	(4)	—	—	—
’25	(1)	(3)	(2)	(2)	(8)
’24	(2)	(2)	(2)	(1)	(7)
’23	(3)	(3)	(3)	(2)	(11)
’22	(4)	(2)	(4)	(3)	(12)
’21	(3)	(3)	(3)	(2)	(12)
’20	(2)	(2)	(2)	(3)	(9)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.34)	(0.36)	—	—	—
’25	(0.41)	(0.45)	(0.44)	(0.15)	(1.45)
’24	(0.47)	(3.62)	(1.54)	(0.85)	(9.08)
’23	(28.35)	(13.23)	(10.26)	(1.53)	(46.80)
’22	(20.53)	(20.53)	(28.09)	(21.56)	(90.91)
’21	(34.58)	(21.61)	(30.25)	(27.01)	(112.38)
’20	(143.71)	(36.74)	(43.22)	(44.30)	(207.46)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	41,580.00	19,008.00	1,603.80	611.82	172.80	107.03	35.10	6.30	1.53	0.97	Analyst estimates 2026–2028 Powerpack
	High	237,600.00	66,528.00	40,154.40	3,118.50	1,473.12	470.88	261.36	110.43	10.35	9.79
People
People	Employees	15	15	9	11	10	12	10	9	5	6
	Revenue/emp, $m	0.00	0.00	0.02	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	0	0	0	0	—	—	—	—	—	—
	Gross margin, %	100.00	100.00	100.00	100.00	0.00	0.00	0.00	—	—	—
	EBT	(9)	(14)	(7)	(9)	(9)	(13)	(11)	(11)	(7)	(9)
	EBT margin, %	(47,336.84)	(93,820.00)	(5,333.33)	(42,419.05)	0.00	0.00	0.00	0.00	0.00	0.00
	Net income	(9)	(12)	(7)	(9)	(9)	(13)	(11)	(11)	(7)	(9)
	Depreciation	0	0	0	0	0	0	0	0	0	0
Per share, $
Per share, $	Revenue	190.00	37.50	115.00	4.88	0.00	0.00	0.00	0.00	0.00	0.00
	Earnings	(97,367.35)	(32,772.43)	(6,174.51)	(2,088.68)	(207.46)	(112.38)	(90.91)	(46.80)	(9.08)	(1.45)
	Cash flow	(77,600.00)	(23,785.00)	(6,266.67)	(2,010.47)	(207.11)	(99.81)	(96.03)	(46.33)	(9.04)	(1.33)
	Capex	(40.00)	(507.50)	(4.17)	(16.74)	(0.45)	(0.43)	(0.96)	(0.02)	0.01	0.00
	Free cash flow	(77,640.00)	(24,292.50)	(6,270.83)	(2,027.21)	(207.55)	(100.24)	(96.99)	(46.35)	(9.03)	(1.34)
	Book value	108,550.00	4,582.50	11,315.00	1,336.74	306.28	184.61	85.81	33.32	6.00	3.37
	Shares, m	0	0	0	0	0	0	0	0	1	6
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	—	—	—	—	—	—
	P/S	63.83	195.04	17.05	32.12	—	—	—	—	—	—
	P/B	0.58	7.13	0.17	0.76	—	—	—	—	—	—
	EV/Sales	(129.54)	140.85	(91.14)	(16.22)	—	—	—	—	—	—
	EV/FCF	1.12	(0.97)	1.63	0.25	—	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	(8)	(10)	(8)	(9)	(9)	(12)	(12)	(11)	(7)	(8)
	Capex	0	0	0	0	0	0	0	0	0	0
	Free cash flow	(8)	(10)	(8)	(9)	(9)	(12)	(12)	(11)	(7)	(8)
Balance, $m
Balance, $m	Working capital	11	2	13	5	13	22	11	8	5	20
	Total debt	—	—	—	0	0	0	0	—	—	—
	Net debt	(13)	(4)	(15)	(7)	(14)	(24)	(12)	(8)	(5)	(21)
	Shareholders’ equity	11	2	14	6	13	22	11	8	5	20
Returns, %
Returns, %	ROA	(90.15)	(142.35)	(75.80)	(76.26)	(73.97)	(64.96)	(60.45)	(97.63)	(94.69)	(63.90)
	ROIC	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	(136.49)	(271.79)	(95.52)	(92.19)	(93.73)	(76.04)	(70.06)	(116.61)	(114.83)	(69.95)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2019 · latest quarter Mar 2019

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
PASG Passage Bio, Inc.	$11.6M	— (loss-making)	—	—	n/m	−59.81% (below 0%: shrinking)	0.00%	0.00%	Compare
PTN Palatin Technologies, Inc.	$11.6M	— (loss-making)	0.2×	−14.06% (below 0%: shrinking)	n/m	+34.21% (above 0%: growing)	100.00%	(1,469.35%)	Compare
CLRB Cellectar Biosciences, Inc.	$11.2M	— (loss-making)	—	−73.23% (below 0%: shrinking)	n/m	−17.49% (below 0%: shrinking)	0.00%	0.00%	Compare
INTS Intensity Therapeutics Inc.	$11.0M	— (loss-making)	—	—	n/m	+4.72% (above 0%: growing)	0.00%	0.00%	Compare
PHIO Phio Pharmaceuticals Corp.	$10.8M	— (loss-making)	— (loss-making)	−8.70% (below 0%: shrinking)	n/m	−58.67% (below 0%: shrinking)	0.00%	0.00%
TPST Tempest Therapeutics, Inc.	$10.7M	— (loss-making)	—	−71.57% (below 0%: shrinking)	n/m	+67.04% (above 0%: growing)	0.00%	0.00%	Compare
KPRX Kiora Pharmaceuticals, Inc.	$10.7M	— (loss-making)	— (loss-making)	−93.64% (below 0%: shrinking)	n/m	+50.06% (above 0%: growing)	100.00%	0.00%	Compare
GDTC CytoMed Therapeutics Limited	$10.3M	— (loss-making)	— (loss-making)	—	n/m	−27.39% (below 0%: shrinking)	0.00%	—	Compare
BLRX BioLineRx Ltd.	$10.2M	— (loss-making)	— (loss-making)	−3.29% (below 0%: shrinking)	n/m	−1,827.71% (below 0%: shrinking)	79.93%	(1,215.31%)	Compare
Median of peers	$10.9M	—	—	−71.57%	—	−6.38%	0.00%	0.00%

All 614 Biotechnology stocks →

Phio Pharmaceuticals Corp. (PHIO) key facts

Phio Pharmaceuticals Corp. (PHIO) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, PHIO traded at $0.87, a market capitalization of $10.8 million.
Return on equity was −70.0% and debt-to-equity 0.00.

Source: company filings (standardised) and stockrow calculations.